HIKL Stock Overview
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 3/6 |
Past Performance | 1/6 |
Financial Health | 4/6 |
Dividends | 5/6 |
Hikma Pharmaceuticals PLC Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£19.17 |
52 Week High | UK£22.23 |
52 Week Low | UK£17.11 |
Beta | 0.44 |
1 Month Change | -0.39% |
3 Month Change | -0.16% |
1 Year Change | 3.57% |
3 Year Change | -21.50% |
5 Year Change | 8.95% |
Change since IPO | 200.23% |
Recent News & Updates
Recent updates
Shareholder Returns
HIKL | GB Pharmaceuticals | GB Market | |
---|---|---|---|
7D | 5.3% | 5.0% | 1.4% |
1Y | 3.6% | 5.0% | 1.1% |
Return vs Industry: HIKL underperformed the UK Pharmaceuticals industry which returned 5% over the past year.
Return vs Market: HIKL exceeded the UK Market which returned 1.1% over the past year.
Price Volatility
HIKL volatility | |
---|---|
HIKL Average Weekly Movement | 3.7% |
Pharmaceuticals Industry Average Movement | 9.1% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: HIKL has not had significant price volatility in the past 3 months.
Volatility Over Time: HIKL's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1978 | 9,100 | Riad Mishlawi | www.hikma.com |
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
Hikma Pharmaceuticals PLC Fundamentals Summary
HIKL fundamental statistics | |
---|---|
Market cap | UK£4.24b |
Earnings (TTM) | UK£152.03m |
Revenue (TTM) | UK£2.30b |
27.9x
P/E Ratio1.8x
P/S RatioIs HIKL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
HIKL income statement (TTM) | |
---|---|
Revenue | US$2.88b |
Cost of Revenue | US$1.47b |
Gross Profit | US$1.41b |
Other Expenses | US$1.22b |
Earnings | US$190.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 08, 2024
Earnings per share (EPS) | 0.86 |
Gross Margin | 48.94% |
Net Profit Margin | 6.61% |
Debt/Equity Ratio | 50.9% |
How did HIKL perform over the long term?
See historical performance and comparison